CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial Gut microbiota induces high platelet response in patients with ST segment elevation myocardial infarction after ticagrelor treatment Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis

Clinical TrialMarch 17, 2019

JOURNAL:N Engl J Med. Article Link

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

DL Bhatt, CV Pollack, JS Lee et al. Keywords: Ticagrelor reversal; oral P2Y12 inhibitor; major bleeding

FULL TEXT PDF